CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has held the Investigator Meeting for the North American clinical investigators participating in the ongoing international Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Inj.). Investigators from 14 clinical centers in Canada and the U.S. who are participating in the Phase III clinical trial for head and neck cancer were in attendance.
Help employers find you! Check out all the jobs and post your resume.
